跳至主要内容
临床试验/CTRI/2025/08/092836
CTRI/2025/08/092836尚未招募2 期

Comparative control clinical study to evaluate efficacy of Bibhitak (Terminalia bellirica) Churn vati in cough

Maharashtra University of Health Sciences,Nashik under the scheme of STRG1 个研究点 分布在 1 个国家目标入组 72 人开始时间: 2025年8月20日最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
72
试验地点
1
主要终点
1) To study the Anti-inflammatory effect of Bibhitak Churna Vati in pharyngitis having Cough.

研究概览

简要总结

Due to change in life style immunity of human being is decreasing spontaneously. At the same time pollution is becoming a big issue day by day this changes are affecting human health, cough, pharangitis, asthama, allergic bronchitis and respiratory disorders are found common in the society specially after Covid-19. There are so many formulations available to treat Cough in market. In Ayurveda simple remedies are mentioned to treat Cough, Asthama and respiratory disorders. As per Astanghridayama a single herb Bibhitak (Terminaliabellirica) is advice for the treatment of Cough, Asthama, Bronchitis. Bhibhitak (Terminalia bellirica) is cheapest medicine, freely available everywhere in India. Need to be tested for efficacy in Cough hence the purpose study is undertaken.We can control cough during the Purvaroopavastha to avoid further progress.The purvaroop mentioned in Ayurveda are pricking pain in the throat i.e.Shukpurnagalasyata, itching in the throat, changes in the voice, etc.Cough is common symptom seen due to pollution now a day. Many formulations are available to treat the same but they are not cost effective. Everyone is not able to afford it. Bibhitak churna vati is a specific formulation consisting of only one herb and that is why it is so cost effective to  afford by poor, needy patients. The drug is proven for its antimicrobial and anti inflammatory activity. The formulation is handy chewable.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • Male and females between 18 to 60 years of age (both inclusive)
  • Subject suffering from uncomplicated cough that does not require antibiotic treatment.
  • The onset time should not be more than 3 days.
  • Willing to sign informed consent.

排除标准

  • Cough caused by bronchial asthma, tuberculosis, bronchiectasis, and other diseases that have been clearly diagnosed as chronic obstructive pulmonary disease and/or severe respiratory tract infection.
  • Patient with known current lung cancer and fibrosis of lung.
  • Patients with uncontrolled diabetes or hypertension.
  • Women during pregnancy or lactation or women who are preparing for pregnancy or lactation during the trial.
  • Subjects with known current serious illness, eg, multisystem failure, chronic liver disease, HIV, cancer, renal failure, serious cardiovascular disease.
  • Known allergy to any ingredient of study products.
  • Any other conditions, which in the opinion of the investigator/s, makes the patient unsuitable for enrollment or could interfere with his/her participation and completion of the study.

结局指标

主要结局

1) To study the Anti-inflammatory effect of Bibhitak Churna Vati in pharyngitis having Cough.

时间窗: 1 week

次要结局

  • 1) To study soothing effect of Bibhitak Churna Vati in Cold.(2) To assess the effect of Bibhitak Churna Vati in dry and wet cough.)

研究者

发起方
Maharashtra University of Health Sciences,Nashik under the scheme of STRG
申办方类型
Other [Health University]
责任方
Principal Investigator
主要研究者

swapnil nanabhau done

Ayurved Seva Sangh Ayurved Mahavidyala, Ganeshwadi ,Panchavati ,Nashik- 03

研究点 (1)

Loading locations...

相似试验